From Webroot@ix.netcom.com Mon Jul 13 00:06:39 1998
Return-Path: <Webroot@ix.netcom.com>
Delivered-To: bguenter@hal.qcc.sk.ca
Received: (qmail 20582 invoked by alias); 13 Jul 1998 00:06:39 -0000
Received: (qmail 20575 invoked from network); 13 Jul 1998 00:06:38 -0000
Received: from linus.vsource.com (qmailr@198.169.201.2)
  by hal.qcc.sk.ca with SMTP; 13 Jul 1998 00:06:38 -0000
Received: (qmail 15419 invoked by uid 559); 12 Jul 1998 23:51:20 -0000
Delivered-To: bguenter@gemprint.com
Received: (qmail 15413 invoked from network); 12 Jul 1998 23:51:19 -0000
Received: from fisherrose-bh.frco.com (206.242.150.66)
  by www.gemprint.com with SMTP; 12 Jul 1998 23:51:19 -0000
Received: (from uucp@localhost) by fisherrose-bh.frco.com (8.6.12/8.6.11) id SAA02922; Sun, 12 Jul 1998 18:57:28 -0500
From: Webroot@ix.netcom.com
Received: from 1cust174.tnt6.tco2.da.uu.net by fisherrose-bh.frco.com via smap (3.2)
	id xmapa1481; Sun, 12 Jul 98 18:54:57 -0500
Date: Sun, 12 Jul 98 19:45:19 EST
To: Webroot@ix.netcom.com
Subject: Cancer Treatment BREAKTHROUGH!!!!
Message-ID: <199807060040.TAA11965@cityatlas.com>
Reply-To: Webroot@ix.netcom.com

DRAMATICALLY EFFECTIVE CANCER 

TREATMENT IN FINAL DEVELOPMENT

FOR SOFT TISSUE CANCERS OF THE

LIVER, BREAST AND LUNGS -  

by a company that just went public last week! 

Now you can participate in the multi-billion
dollar cancer treatment industry by owning 
stock in this company before the "Wall Street
Analysts" discover it. The company is in 
the final stages of researching and 
developing this new drug to help cure soft  
tissue cancers of the liver, breast and lungs.

This company is led by a very distinguished 
team of Cancer Research Specialists who have
studied this disease for the last two decades.
The company holds the worldwide manufacturing
and marketing rights (except for the former
Soviet Union) for this drug. 

The company is called :

NuOncology Labs Inc.

Trading Symbol: NLAB

Trades:   OTC  BB

'NLAB' started trading last Thursday,July 9,
at: $5 15/32

At the market close Friday, July 10, it was:
$6 1/8

Trials are now being conducted on over 200 
human cancer patients with this new drug and
some very important announcements are 
expected to come from NuOncology over the 
next few weeks.

To have complete investor information sent to 
you via e-mail on this innovative new 
pharmaceutical research and development 
company just :

<a href="mailto:news@requested-info.com">Click Here</a>

You will get back complete information via
e-mail within the next 24 hours on :
  
NuOncology Labs, Inc. 

We profile companies at the time they initially
go public - before they have been discovered 
by 'The Street' and financial media and have 
by that time already doubled or tripled in price.
By requesting additional information on 
NuOncology Labs, Inc., you are also requesting 
a subscription to our newsletter that profiles
emerging new companies. There is no obligation
and absolutely no cost to you. You may 
unsubscribe at any time. 

